These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 36988207)

  • 41. Mesoporous silica nanoparticles in nanomedicine applications.
    Manzano M; Vallet-Regí M
    J Mater Sci Mater Med; 2018 May; 29(5):65. PubMed ID: 29737405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nanomedicine as a promising strategy for the theranostics of infectious diseases.
    Liu H; Zhong W; Zhang X; Lin D; Wu J
    J Mater Chem B; 2021 Oct; 9(38):7878-7908. PubMed ID: 34611689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Renal Nano-drug delivery for acute kidney Injury: Current status and future perspectives.
    Geo HN; Murugan DD; Chik Z; Norazit A; Foo YY; Leo BF; Teo YY; Kadir SZSBSA; Chan Y; Chai HJ; Medel M; Abdullah NA; Johns EJ; Vicent MJ; Chung LY; Kiew LV
    J Control Release; 2022 Mar; 343():237-254. PubMed ID: 35085695
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer's Disease: A State-of-the-Art (2017-2020).
    Binda A; Murano C; Rivolta I
    Int J Nanomedicine; 2020; 15():6113-6135. PubMed ID: 32884267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Extracellular vesicles for renal therapeutics: State of the art and future perspective.
    Tang TT; Wang B; Lv LL; Dong Z; Liu BC
    J Control Release; 2022 Sep; 349():32-50. PubMed ID: 35779658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
    Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
    Scand J Gastroenterol; 2019 Jan; 54(1):18-26. PubMed ID: 30678499
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Voyage of theranostic liposomes for imaging and therapy.
    Sachin M; Sachin D; Dinesh S
    J Cosmet Laser Ther; 2017 Aug; 19(4):245-249. PubMed ID: 28135901
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ignoring the modeling approaches: Towards the shadowy paths in nanomedicine.
    Hassanzadeh P; Atyabi F; Dinarvand R
    J Control Release; 2018 Jun; 280():58-75. PubMed ID: 29723612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the Kidneys at the Nanoscale: Nanotechnology in Nephrology.
    Vasylaki A; Ghosh P; Jaimes EA; Williams RM
    Kidney360; 2024 Apr; 5(4):618-630. PubMed ID: 38414130
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synergistic Nanomedicine: Passive, Active, and Ultrasound-Triggered Drug Delivery in Cancer Treatment.
    Elkhodiry MA; Momah CC; Suwaidi SR; Gadalla D; Martins AM; Vitor RF; Husseini GA
    J Nanosci Nanotechnol; 2016 Jan; 16(1):1-18. PubMed ID: 27398430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical application of nano-targeting for enhancing chemotherapeutic efficacy and safety in cancer management.
    Phillips MC; Mousa SA
    Nanomedicine (Lond); 2022 Mar; 17(6):405-421. PubMed ID: 35118878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.
    Miller-Kleinhenz JM; Bozeman EN; Yang L
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(6):797-816. PubMed ID: 25966677
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Linkers: The key elements for the creation of efficient nanotherapeutics.
    Hassanzadeh P; Atyabi F; Dinarvand R
    J Control Release; 2018 Jan; 270():260-267. PubMed ID: 29246786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The potential role of nanomedicine on COVID-19 therapeutics.
    Mainardes RM; Diedrich C
    Ther Deliv; 2020 Jul; 11(7):411-414. PubMed ID: 32594863
    [No Abstract]   [Full Text] [Related]  

  • 55. Nanoformulations for Targeted Drug Delivery to Prostate Cancer: An Overview.
    Hema S; Thambiraj S; Shankaran DR
    J Nanosci Nanotechnol; 2018 Aug; 18(8):5171-5191. PubMed ID: 29458568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advances in intelligent-responsive nanocarriers for cancer therapy.
    Tian M; Xin X; Wu R; Guan W; Zhou W
    Pharmacol Res; 2022 Apr; 178():106184. PubMed ID: 35301111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples.
    Zhang RX; Li J; Zhang T; Amini MA; He C; Lu B; Ahmed T; Lip H; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2018 May; 39(5):825-844. PubMed ID: 29698389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nanomedicines for renal disease: current status and future applications.
    Kamaly N; He JC; Ausiello DA; Farokhzad OC
    Nat Rev Nephrol; 2016 Dec; 12(12):738-753. PubMed ID: 27795549
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted nanomedicines for the treatment of bone disease and regeneration.
    Ordikhani F; Zandi N; Mazaheri M; Luther GA; Ghovvati M; Akbarzadeh A; Annabi N
    Med Res Rev; 2021 May; 41(3):1221-1254. PubMed ID: 33347711
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Curcumin nanoformulations: Beneficial nanomedicine against cancer.
    Maleki Dizaj S; Alipour M; Dalir Abdolahinia E; Ahmadian E; Eftekhari A; Forouhandeh H; Rahbar Saadat Y; Sharifi S; Zununi Vahed S
    Phytother Res; 2022 Mar; 36(3):1156-1181. PubMed ID: 35129230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.